Literature DB >> 9050972

An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-aldosterone system.

I Komiya1, T Yamada, N Takasu, T Asawa, H Akamine, N Yagi, Y Nagasawa, H Ohtsuka, Y Miyahara, H Sakai, A Sato, T Aizawa.   

Abstract

OBJECTIVE: The role of the renin-aldosterone system and the ability of renal sodium reabsorption to facilitate pressure natriuresis were analyzed by using a sufficient number of Japanese patients with essential hypertension.
METHODS: We studied 3222 normal Japanese subjects (610 in Kashiwa City Hospital and 2612 in Shinshu University Hospital), 741 Japanese patients with essential hypertension (256 in Kashiwa City Hospital and 485 in Shinshu University Hospital), 20 patients with aldosterone-producing adenomas and 11 patients with idiopathic hyperaldosteronism to determine the possible roles of sodium, renal function, and plasma aldosterone concentration (PAC) on blood pressure elevation. Inappropriate elevation of aldosterone levels [elevation of the aldosterone:plasma renin activity (PRA) ratio] was used to assess aldosterone action.
RESULTS: The peak of the serum sodium distribution curve was approximately 2 mmol/l higher in the patients with essential hypertension than it was in controls. The prevalence of higher serum sodium concentrations (> or = 147 mmol/l) also was increased significantly hypertensive patients. Age-related deterioration of renal function did not explain the hypertension and abnormal sodium metabolism in the hypertensive patients. In stepwise regression analysis, the serum sodium concentration was related inversely to the PRA and positively to the PAC:PRA ratio. Although there was an inverse relationship between urinary sodium excretion (representing sodium intake) and the PRA, urinary sodium excretion proved not to be significant as a source of variation in the PAC or in the PAC:PRA ratio in the hypertensive patients. Although the PAC was within the normal range in patients with serum sodium concentrations of 147 mmol/l or more and an elevated PAC:PRA ratio, it was inappropriately high for the stimulus applied, as indicated by the PRA; this is similar to the situation with aldosterone-producing adenomas or idiopathic hyperaldosteronism.
CONCLUSION: Serum sodium distribution patterns differed between normal subjects and patients with essential hypertension in this Japanese population. The deterioration of renal function and increased sodium intake did not explain this abnormal sodium metabolism. A higher serum sodium concentration is related to an elevated blood pressure, and, in some patients, an inappropriate elevation of plasma aldosterone levels. Of the Japanese hypertensive patients, 10-14% exhibited serum sodium concentrations of 147 mmol/l or more and inappropriate elevations of aldosterone level (suppressed PRA and normal aldosterone level). The defect in these patients presumably lies in the inappropriately high secretion of aldosterone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9050972     DOI: 10.1097/00004872-199715010-00006

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  14 in total

1.  Association between pre hemodialysis serum sodium concentration and blood pressure: results from a retrospective analysis from the international monitoring dialysis outcomes (MONDO) initiative.

Authors:  J G Raimann; B Canaud; M Etter; J P Kooman; N W Levin; D Marcelli; C Marelli; A Power; N Duncan; F M van der Sande; P Carioni; S Thijssen; X Xu; L A Usvyat; Y Wang; P Kotanko
Journal:  J Hum Hypertens       Date:  2015-07-30       Impact factor: 3.012

2.  Primary aldosteronism associated with subclinical Cushing syndrome.

Authors:  K Fujimoto; S Honjo; H Tatsuoka; Y Hamamoto; Y Kawasaki; A Matsuoka; H Ikeda; Y Wada; H Sasano; H Koshiyama
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

3.  Serum Sodium and Pulse Pressure in SPRINT.

Authors:  Kristen L Nowak; Michel Chonchol; Anna Jovanovich; Zhiying You; Jeffrey Bates; Capri Foy; Stephen Glasser; Anthony A Killeen; John Kostis; Carlos J Rodriguez; Mark Segal; Debra L Simmons; Addison Taylor; Laura C Lovato; Walter T Ambrosius; Mark A Supiano
Journal:  Am J Hypertens       Date:  2019-06-11       Impact factor: 2.689

Review 4.  Hypertension and the expanding role of aldosterone.

Authors:  Scott M Mackenzie; John Connell
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

Review 5.  Sympathetic Nervous System Contributions to Hypertension: Updates and Therapeutic Relevance.

Authors:  Leon J DeLalio; Alan F Sved; Sean D Stocker
Journal:  Can J Cardiol       Date:  2020-03-06       Impact factor: 5.223

6.  Combined effect of hyperuricemia and overweight/obesity on the prevalence of hypertension among US adults: result from the National Health and Nutrition Examination Survey.

Authors:  G-M Han; S Gonzalez; D DeVries
Journal:  J Hum Hypertens       Date:  2014-05-01       Impact factor: 3.012

Review 7.  Salt and sugar: their effects on blood pressure.

Authors:  Feng J He; Graham A MacGregor
Journal:  Pflugers Arch       Date:  2014-12-30       Impact factor: 3.657

8.  Interindividual variation in serum sodium and longitudinal blood pressure tracking in the Framingham Heart Study.

Authors:  Rodrigo M Lago; Michael J Pencina; Thomas J Wang; Katherine J Lanier; Ralph B D'Agostino; William B Kannel; Ramachandran S Vasan
Journal:  J Hypertens       Date:  2008-11       Impact factor: 4.844

9.  Elevated sodium and dehydration stimulate inflammatory signaling in endothelial cells and promote atherosclerosis.

Authors:  Natalia I Dmitrieva; Maurice B Burg
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

10.  Small increases in plasma sodium are associated with higher risk of mortality in a healthy population.

Authors:  Se Won Oh; Seon Ha Baek; Jung Nam An; Ho Suk Goo; Sejoong Kim; Ki Young Na; Dong Wan Chae; Suhnggwon Kim; Ho Jun Chin
Journal:  J Korean Med Sci       Date:  2013-07-03       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.